Scientists today are able to observe tumor cells in increasing detail and thus gain a better understanding of how cancer cells differ from healthy ones. Doctors and scientists from the National Center for Tumor Diseases (NCT), the Institute of Pathology at Heidelberg University Hospital (UKHD) and the German Cancer Consortium (DKTK) completed a prospective study that systematically verified data on cancer genome analysis. Conducted over a period of three years, the study examined more than 200 patients with tumor diseases that are at an advanced stage or difficult to treat who underwent a cancer genome analysis within the scope of the NCT/DKTK-MASTER program. In the validation study as part of the program, the scientists show how comprehensive cancer genome analysis and evaluation can be optimized in such a way that they can be used for clinical application.
Original publication: A. Lier, R. Penzel, C. Heining et al. (2018) Validating Comprehensive Next-Generation Sequencing Results for Precision Oncology: The NCT/DKTK MASTER Experience. JCO Precision Oncology. DOI 10.1200/PO.18.00171
Read more: NCT Press Release